i2a

i2a is a French company based in Montpellier, specializing in microbiological diagnostics with a strong emphasis on bacteriology and antibiotic susceptibility testing. Founded in 1988, the company develops automated systems, reagents, and software to enhance workflows in clinical microbiology laboratories. Their flagship products include the RECITALS range of automated equipment, which aids labs in efficiently conducting antibiograms. With a presence in over 20 countries, i2a serves more than 500 public and private laboratories, focusing on advanced tools for antibiotic resistance detection and epidemiological surveillance. The company also supports a user network called REUSSIR, dedicated to public health initiatives and combating antibiotic resistance. i2a is committed to maintaining high standards through a robust quality management system and emphasizes values such as diversity, gender equality, and environmental responsibility. Since 2021, i2a has been owned by Apposite Capital and continues to innovate in automated microbiological diagnostics.

• Employees 130
• Founded 1988